The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. - Wikidata - wikimedia - TriplyDB

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.

http://www.wikidata.org/entity/Q33986683

about

Epigenetic therapy in gastrointestinal cancer: the right combination Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies Molecular phenotypes of colorectal cancer and potential clinical applications The molecular background of mucinous carcinoma beyond MUC2 The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer.CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.CpG island methylator phenotype and prognosis of colorectal cancer in Northeast China.Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers.Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer.Correlation between smoking history and molecular pathways in sporadic colorectal cancer: a meta-analysis.Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX.Tracking the Correlation Between CpG Island Methylator Phenotype and Other Molecular Features and Clinicopathological Features in Human Colorectal Cancers: A Systematic Review and Meta-Analysis.CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer.How many diseases are colorectal cancer?Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.Estimated mean sojourn time associated with hemoccult SENSA for detection of proximal and distal colorectal cancer.Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.Prognostic and predictive value of CpG island methylator phenotype in patients with locally advanced nonmetastatic sporadic colorectal cancer.Epigenetic biomarkers in colorectal cancer diagnostics.Genomics and epigenomics of colorectal cancer.DNA methylation and personalized medicine.Luminally expressed gastrointestinal biomarkers.The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.DNA methylation aberrancies as a guide for surveillance and treatment of human cancers.Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer.Methylation subtypes and large-scale epigenetic alterations in gastric cancer.Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.Colorectal cancer: epigenetic alterations and their clinical implications.DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies.Infrequently expressed miRNAs influence survival after diagnosis with colorectal cancer.Colorectal cancer-susceptibility single-nucleotide polymorphisms in Korean population.CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instability.CpG island methylator phenotype of myelodysplastic syndrome identified through genome-wide profiling of DNA methylation and gene expression.

P2860

Q26745709-2D5A913C-9A60-4B62-9AD3-74AD3C8A3A4F Q26751035-5B7A1607-4873-4444-A5A9-5905DF516231 Q26768471-9BF0B488-7A44-43C0-B72A-34C2939CF3B6 Q26772276-9D2BE53E-7590-463A-930A-10344ED65E25 Q26785725-675F3810-52F5-43EA-8E4C-5ADB1D9DF0A9 Q28083904-D041C86A-AAB7-4730-96D3-314B31C0DE3A Q33630343-79E91AFF-FCE3-48D0-9193-B30B974DCA59 Q34050656-DF824C7D-5DDA-49F2-9F1C-74C4CC5EC9DA Q34084652-7F58F0C9-5771-49E7-A327-E45F854373A5 Q34177058-C94C9EAE-8DA9-4AA2-A7DF-81DA20BAF11E Q34487177-AC8EB53E-7278-4517-8BDF-97B240489FDB Q34553646-11DCEA1D-3C9B-43BE-A4C7-FB81B29B6512 Q35138892-6F960979-7833-4E3C-A46C-E852C768ACDF Q35643491-7DF933D7-AF9F-4C88-90FE-F6E33946EF1D Q35831602-234E8B06-5872-4C3F-9415-0CC420D8B5BA Q35952149-3F1C17C6-94F1-4A01-97F3-D52BF08CDD6B Q36075933-DAFC4D75-7E29-45EC-8D0E-990ED44C4C85 Q36238965-A6ED4646-B20A-41C1-8557-72F87B241A21 Q36463826-63F0E52D-F1E8-44E9-95DB-0C781ED13941 Q36569142-F05CDCC1-25BC-49AD-A3E8-DD1C2C0B0091 Q36893961-667178D1-F3A9-4773-B8AB-AFF471D82781 Q37100708-AAE7508E-9F84-4345-B2ED-82108FD311C0 Q37708015-EB67CC18-9831-459F-AB07-7CD47491AAC7 Q37733784-EBCB84E9-D98B-415E-98DB-F32BA7E1C15E Q38018997-8A1242A3-4A2F-4986-9666-B9EF7302199D Q38074617-A804F2BB-AD35-4826-8823-0254E7EB874D Q38250428-8EC1F7EE-DB47-450E-8D36-E80B1581D7AB Q38636313-D94460CF-E3FD-4109-8074-50E7DDC1A0D4 Q38730744-3DD8E4C5-D392-4E8D-973D-E956DEA11BB1 Q39208639-46309AA9-8349-4010-8885-C6FAD23BEFA8 Q43572389-A940B9AF-1782-48E7-8E59-28B1D1CDEBCD Q43936243-BA5ECA3F-431F-4CC6-840F-3F7D747E328A Q45141920-E3183DFB-9956-4F77-BBB7-122875230CBF Q46112381-0468D2AF-A14F-4333-B93A-C9356C4401E2 Q46181764-4092DE43-5B34-48B0-B6F0-BCF84CF8252A Q46465597-42CBC56F-FA2B-4F1B-B03E-C3B17E7FE388 Q47960541-C8ECE705-EB41-451B-9E07-41C1453B7FF8 Q50607666-EE016C60-9E53-47A1-95A3-35B4EC2A754D Q51135450-CB96D859-35D9-42A2-A5C8-AEDB80F2EA50 Q54219654-CA4994F3-8C22-4096-9C18-C08D3CCC21F1

P2860

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.

http://www.wikidata.org/entity/Q33986683

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

The CpG island methylator phen ...... e-based adjuvant chemotherapy.

@ast

The CpG island methylator phen ...... e-based adjuvant chemotherapy.

@en

type

label

The CpG island methylator phen ...... e-based adjuvant chemotherapy.

@ast

The CpG island methylator phen ...... e-based adjuvant chemotherapy.

@en

prefLabel

The CpG island methylator phen ...... e-based adjuvant chemotherapy.

@ast

The CpG island methylator phen ...... e-based adjuvant chemotherapy.

@en

P1433

Q33986683-C5D4F8DA-7006-4D1F-9111-B29B19D772EF

P1476

Q33986683-E2847DD3-445E-4CDE-BDDC-C7D22EC19CF8

P2093

Q33986683-31321FAE-593C-478C-B5E3-B3C485914FE3

Q33986683-4D9CF6D1-4EB6-4C68-81DA-F159FB476E95

Q33986683-4DCBEE4B-7970-41C9-9DBF-BD2DDCDB8644

Q33986683-4E196081-93DF-4816-87EE-2672D25CB8FE

Q33986683-51523C23-1B35-486E-9FC2-46B3F3B1A6F2

Q33986683-70B0E990-E7E4-4EBC-8E0F-A763715E067F

Q33986683-7F4C02BF-584E-407B-8F88-9311A4F2DC41

Q33986683-B7037032-9DF9-4308-835E-5F9EF3E4CC24

Q33986683-D8650ED5-59FC-4738-B594-F7CE52FE7484

Q33986683-FE327129-A4C4-43EE-BB58-3B98B029A21E

P2860

Q33986683-06A3EC80-699A-480A-9099-12B2E3DA9BBE

Q33986683-0783B15D-5513-4C85-B52A-B37A16189EF9

Q33986683-2500CE19-45B2-4774-BBA4-F39F7A6025D8

Q33986683-309794E6-3EAC-49F2-B65A-86727BB40E93

Q33986683-39EA2240-BCD5-47CF-8DEC-D08FF4E64113

Q33986683-3A76DAAC-12AC-4E4D-B344-CD7D1EA204D0

Q33986683-3CE22D81-7E82-40CB-9238-81F155DC81C4

Q33986683-3DBB6E29-89C6-4297-A3DC-D4E1553E15A4

Q33986683-474C60F9-7549-4B26-A236-51E8FA473F6D

Q33986683-54330F02-D2E5-4781-B048-E61D91A327C8

P2888

Q33986683-F352B96D-1FA2-4A10-ACE8-2D3746DC3DC9

P304

Q33986683-BBABFFCA-291C-4D94-BE31-0BE17CFE9104

P31

Q33986683-B36DA4FF-4C9B-4E5F-BFAF-D6DB17C7632C

P356

Q33986683-85FF1E50-7EE6-4147-94E7-66EE634C5AE9

P407

Q33986683-354245DB-F2F6-49F6-A3C3-6EABCB484F15

P478

Q33986683-2333F68C-0B8B-41E4-8148-3A83E98BC447

P50

Q33986683-AB6FBF82-A8C8-41A2-A2AF-8C04C998F964

P577

Q33986683-62D3087E-83A6-4E21-8DFD-2555E2D8B230

P5875

Q33986683-1FEE28FD-4D27-4DA3-85E1-56DE64972E28

P6179

Q33986683-8985AF30-7D24-46D8-9D46-B3307EFC926C

P698

Q33986683-23D36AD7-CDF1-4E69-8450-DA822A711DBF

P921

Q33986683-B24D8AB7-2718-4E0D-B823-7089D1C7571C

P932

Q33986683-1363FEFE-D16E-4A62-B6DE-FE653B119EE5

P356

1471-2407-11-344

P1433

P1476

The CpG island methylator phen ...... e-based adjuvant chemotherapy.

@en

P2093

Byung-Hoon Min

http://www.w3.org/2001/XMLSchema#string

Cheol Keun Park

http://www.w3.org/2001/XMLSchema#string

Dong Kyung Chang

http://www.w3.org/2001/XMLSchema#string

Eui Jin Lee

http://www.w3.org/2001/XMLSchema#string

Hee Cheol Kim

http://www.w3.org/2001/XMLSchema#string

Hong Suk Yu

http://www.w3.org/2001/XMLSchema#string

Jeong Mo Bae

http://www.w3.org/2001/XMLSchema#string

Kyoung-Mee Kim

http://www.w3.org/2001/XMLSchema#string

Suk-Hee Lee

http://www.w3.org/2001/XMLSchema#string

Young-Ho Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

CpG island methylator phenotype in colorectal cancer

A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer

Molecular predictors of survival after adjuvant chemotherapy for colon cancer

CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer

Combination of O6-methylguanine-DNA methyltransferase and thymidylate synthase for the prediction of fluoropyrimidine efficacy.

Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.

Understanding the interaction between environmental exposures and molecular events in colorectal carcinogenesis.

MGMT promoter methylation and field defect in sporadic colorectal cancer.

Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands.

P2888

1471-2407-11-344

P304

344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-11-344

http://www.w3.org/2001/XMLSchema#string

P407

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Gyeong Hoon Kang

P577

2011-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51558032

http://www.w3.org/2001/XMLSchema#string

P6179

1044957790

http://www.w3.org/2001/XMLSchema#string

P698

21827707

http://www.w3.org/2001/XMLSchema#string

P921

P932

3162585

http://www.w3.org/2001/XMLSchema#string